RE:RemidoseRemains to be seen how Labs leverages this. But for now:
- This is non dilutive
- Is fully complementary with labs offerings, not competing with current brands and lines of product.
- No significant capex to bring in manufacturing inhouse. Therefore optimizing labs facilities utilization without splurging cash.
- Has current sales, however small they may be.
Considering labs has not disclosed sales amounts and this looking like wildlife deal, remidose was probably on the verge of collapse. Removing all costs related to remidose facilities, mgmt, hr might make this an interesting opportunity.